RT info:eu-repo/semantics/article
T1 Comparative efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia treatment: a meta-analysis of clinical trials and Real-World outcomes
A1 Sanz Solas, Antonio
A1 Saiz Rodríguez, Miriam
A1 Calvo Simal, Sara
A1 Rodríguez-Veiga, Rebeca
A1 Solana-Altabella, Antonio
A1 Montesinos, Pau
A1 Labrador Gómez, Jorge
K1 Cáncer-Tratamiento
K1 Cancer-Treatment
K1 Leucemia mieloide
K1 Myeloid leukemia
AB This meta-analysis, comprising 24 studies, evaluated the efficacy of venetoclax (VEN) in combination with hypomethylat-ing agents (HMAs), including azacitidine (AZA) and decitabine (DEC), in untreated patients with acute myeloid leukemia (AML), comparing outcomes from clinical trials and real-world practice. No significant difference in composite complete response (CRc) rates was observed between clinical trials (52%, 95% CI: 39–65%) and real-world studies (67%, 95% CI: 47–87%). However, overall survival (OS) was significantly longer in clinical trials (13.98 months, 95% CI: 11.89–16.07) compared to real-world cohorts (9.35 months, 95% CI: 8.46–10.23; p < 0.005). In real-world studies, the VEN + HMA combination was associated with a significantly higher CRc rate (67%, 95% CI: 48–85%) compared to HMA monotherapy (17%, 95% CI: 13–21%; p < 0.005), although no significant difference in OS was observed between these groups (9.35 vs. 9.38 months; p = 0.964). These findings highlight the need to optimize the implementation of VEN + HMA regimens in clinical practice, as real-world outcomes remain inferior to those reported in clinical trials.
PB Springer
SN 0939-5555
YR 2025
FD 2025-08
LK https://hdl.handle.net/10259/11906
UL https://hdl.handle.net/10259/11906
LA eng
NO A.S.S contract was funded by Fundación hna, 2nd edition of the Scientific Health Research Award. M.S.R. contract was supported by Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation, through the Sara Borrell Program (CD21/00022).
DS Repositorio Institucional de la Universidad de Burgos
RD 11-jul-2026